Patent · US Active

Use of car and bite technology coupled with an ScFv from an antibody against human thymidine kinase 1 to specifically target tumors

US10828355B2 · kind B2 · utility

0Cited by
4References
8Claims
0Family size

Inventors

Key dates

Filing dateSep 5, 2018
Grant dateNov 10, 2020
Priority date—
Expiry dateDec 6, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/03
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Modified T-cells have paratopes against human TK1 epitopes, are made by producing monoclonal antibodies that are specific to TK1, creating chimeric antigen receptors (CARs) by fusion of the single-chain variable fragments (scFv) of the monoclonal antibodies to T-cell signalling domains, and transducing the CARs to the T-cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.